{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:37:17Z","timestamp":1784122637951,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T09:19:47Z","timestamp":1593163187000},"page":"5480-5489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230"],"prefix":"10.1016","volume":"38","author":[{"given":"Puthupparampil V.","family":"Scaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth B.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Muratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Barnafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan U.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4876","authenticated-orcid":false,"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-5402","authenticated-orcid":false,"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-5005","authenticated-orcid":false,"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.018_b0005","doi-asserted-by":"crossref","unstructured":"mal ERACGoV: A research agenda for malaria eradication: vaccines. PLoS Med 2011;8:e1000398.","DOI":"10.1371\/journal.pmed.1000398"},{"key":"10.1016\/j.vaccine.2020.06.018_b0010","unstructured":"Organization WH: World Malaria Report 2019. WHO ed. pp. 23. Geneva, Switzerland: WHO; 2019:232."},{"key":"10.1016\/j.vaccine.2020.06.018_b0015","unstructured":"Ballou WR. Malaria Vaccines. In: Plotkin's Vaccines. 7th ed. Edited by S.A. P, W. O, A. P, P.A. O, Edwards KM: Elsevier; 2018: 561566."},{"key":"10.1016\/j.vaccine.2020.06.018_b0020","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1172\/JCI44423","article-title":"Advances and challenges in malaria vaccine development","volume":"120","author":"Crompton","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.06.018_b0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1586\/erv.12.92","article-title":"Pre-erythrocytic malaria vaccines: identifying the targets","volume":"11","author":"Duffy","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.018_b0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/14760584.2016.1141680","article-title":"Progress and prospects for blood-stage malaria vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.018_b0035","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young African children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.018_b0040","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0045","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals","volume":"174","author":"Barr","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.06.018_b0050","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/S0264-410X(00)00521-1","article-title":"Transmission blocking malaria vaccines","volume":"19","author":"Carter","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12936-016-1163-3","article-title":"Transmission-blocking strategies: the roadmap from laboratory bench to the community","volume":"15","author":"Goncalves","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.06.018_b0060","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1128\/iai.62.12.5576-5580.1994","article-title":"Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum","volume":"62","author":"Kaslow","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.06.018_b0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.apar.2015.04.001","article-title":"Development of malaria transmission-blocking vaccines: from concept to product","volume":"89","author":"Wu","year":"2015","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2020.06.018_b0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2019.1561289","article-title":"Malaria vaccines in the eradication era: current status and future perspectives","volume":"18","author":"Wilson","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.018_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119335","article-title":"Recombinant Pvs48\/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes","volume":"10","author":"Arevalo-Herrera","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006352","article-title":"A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48\/45 expressed in Escherichia coli","volume":"4","author":"Chowdhury","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jinf.2015.03.007","article-title":"Naturally acquired antibody responses to recombinant Pfs230 and Pfs48\/45 transmission blocking vaccine candidates","volume":"71","author":"Jones","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2020.06.018_b0090","doi-asserted-by":"crossref","first-page":"11193","DOI":"10.1038\/srep11193","article-title":"Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum","volume":"5","author":"Kapulu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.06.018_b0095","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and immunological characterization of recombinant 6-cysteine domains of the plasmodium falciparum sexual stage protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.06.018_b0100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/14760584.2015.993383","article-title":"Toward the development of effective transmission-blocking vaccines for malaria","volume":"14","author":"Nikolaeva","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.018_b0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12936-015-0972-0","article-title":"Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants","volume":"14","author":"Roeffen","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.06.018_b0110","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.vaccine.2015.02.040","article-title":"A Plasmodium falciparum 48\/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies","volume":"33","author":"Singh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/CVI.05104-11","article-title":"N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity","volume":"18","author":"Tachibana","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.06.018_b0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0166-6851(94)00054-Q","article-title":"Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48\/45 and Pf12","volume":"71","author":"Carter","year":"1995","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2020.06.018_b0125","doi-asserted-by":"crossref","first-page":"13598","DOI":"10.1073\/pnas.0502378102","article-title":"Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum","volume":"102","author":"Gerloff","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.06.018_b0130","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1073\/pnas.0800459105","article-title":"Correctly folded Pfs48\/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice","volume":"105","author":"Outchkourov","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.06.018_b0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12936-019-2989-2","article-title":"The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate","volume":"18","author":"Lee","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.06.018_b0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12934-017-0710-0","article-title":"Construct design, production, and characterization of Plasmodium falciparum 48\/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine","volume":"16","author":"Singh","year":"2017","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.vaccine.2020.06.018_b0145","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2019.02.021","article-title":"Identification of domains within Pfs230 that elicit transmission blocking antibody responses","volume":"37","author":"Tachibana","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221733","article-title":"Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity","volume":"14","author":"Chan","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079538","article-title":"A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice","volume":"8","author":"Jones","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0160","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2015.08.025","article-title":"Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles","volume":"33","author":"Kumar","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-019-0121-9","article-title":"Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230","volume":"4","author":"Scaria","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.018_b0170","doi-asserted-by":"crossref","first-page":"18243","DOI":"10.1073\/pnas.0608545103","article-title":"Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex","volume":"103","author":"Wu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.06.018_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138761","article-title":"A method for producing protein nanoparticles with applications in vaccines","volume":"11","author":"Jones","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0180","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","author":"Shimp","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.micinf.2008.12.009","article-title":"Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure","volume":"11","author":"Qian","year":"2009","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2020.06.018_b0190","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1016\/j.vaccine.2007.02.073","article-title":"Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates","volume":"25","author":"Qian","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.018_b0195","doi-asserted-by":"crossref","first-page":"40312","DOI":"10.1038\/srep40312","article-title":"Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate","volume":"7","author":"Radtke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.06.018_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190312","article-title":"Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity","volume":"12","author":"Scaria","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0205","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"Safety and immunogenicity of Pfs25H-EPA\/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.018_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: an open label study in malaria naive adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.018_b0215","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.018_b0220","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.xphs.2018.03.002","article-title":"Analytical comparability assessments of 5 recombinant CRM197 proteins from different manufacturers and expression systems","volume":"107","author":"Hickey","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2020.06.018_b0225","doi-asserted-by":"crossref","unstructured":"Tsai CW, Duggan PF, Shimp RL, Jr., Miller LH, Narum DL: Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol 2006;121: 458\u201370.","DOI":"10.1016\/j.jbiotec.2005.08.025"},{"key":"10.1016\/j.vaccine.2020.06.018_b0230","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00216-002-1347-2","article-title":"Quick measurement of protein sulfhydryls with Ellman's reagent and with 4,4'-dithiodipyridine","volume":"373","author":"Riener","year":"2002","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.vaccine.2020.06.018_b0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0022-1759(92)90020-T","article-title":"A simplified method for determination of peptide-protein molar ratios using amino acid analysis","volume":"156","author":"Shuler","year":"1992","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.06.018_b0240","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.vaccine.2018.04.035","article-title":"Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever","volume":"36","author":"An","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2020.06.018_b0245","doi-asserted-by":"crossref","first-page":"eaas9930","DOI":"10.1126\/sciadv.aas9930","article-title":"The adjuvant GLA-AF enhances human intradermal vaccine responses","volume":"4","author":"Carter","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2020.06.018_b0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.06.018_b0255","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/biot.201400395","article-title":"Outer membrane vesicles as platform vaccine technology","volume":"10","author":"van der Pol","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2020.06.018_b0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-020-0173-x","article-title":"Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment","volume":"18","author":"Huang","year":"2020","journal-title":"npj Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:24Z","timestamp":1759401924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20307908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":52,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20307908"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}